Literature DB >> 12823230

The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse.

Kyoko Imanaka-Yoshida1, Kenn-ichi Matsumoto, Mari Hara, Teruyo Sakakura, Toshimichi Yoshida.   

Abstract

One of a family of extracellular matrix proteins, tenascin-C (TNC) is expressed in a spatiotemporally restricted pattern associated with tissue remodeling during embryonic development, wound healing, cancer invasion and tissue regeneration. Another form, tenascin-X (TNX), is found in most tissues but most predominantly in heart and muscle, often complementarily to TNC. The present analysis demonstrated their expression during early heart development, using mouse lines containing the lacZ gene targeted to the TNC locus, by RT-PCR, immunohistochemistry, and in situ hybridization. TNC was transiently expressed at important steps during heart development: (1) precardiac mesodermal cells differentiating to cardiomyocytes and endocardial cells at E 7.5 - 8.5; (2) cardiomyocytes in the outflow tract at E 8.5 - 12; (3) endocardial cells forming cushion tissue at E 9.5 - 13; and (4) mesenchymal cells in the proepicardial organ (PEO), the precursors of coronary vessels, at E 9.5. When PEO cells were transferred onto the heart surface, the expression of TNC was downregulated, while TNX was upregulated at E 11. Initially, epicardial cells around the AV groove and atrium started to express TNX. TNX-positive cells then gradually spread all over the entire surface of the heart and invaded and formed primitive vascular channels in the myocardium. Despite restricted expression at important sites and steps during cardiogenesis, the hearts of TNC deficient mice developed normally. No difference in the expression pattern of TNX were observed in TNC knockout and wild mice. These results suggest; (1) TNC could play important roles in the differentiation of cardiomyocytes and the early morphogenesis of the heart; (2) TNX could be involved in coronary vasculogenesis; (3) TNX does not compensate for the loss of TNC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823230     DOI: 10.1046/j.1432-0436.2003.7104506.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  27 in total

Review 1.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade.

Authors:  Shuichi Fujita; Naoshi Shimojo; Fumio Terasaki; Kaoru Otsuka; Noriko Hosotani; Yuka Kohda; Takao Tanaka; Tomohiro Nishioka; Toshimichi Yoshida; Michiaki Hiroe; Yasushi Kitaura; Nobukazu Ishizaka; Kyoko Imanaka-Yoshida
Journal:  Heart Vessels       Date:  2013-01-01       Impact factor: 2.037

3.  Morphogenesis of the right ventricle requires myocardial expression of Gata4.

Authors:  Elisabeth M Zeisberg; Qing Ma; Amy L Juraszek; Kelvin Moses; Robert J Schwartz; Seigo Izumo; William T Pu
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

4.  Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Authors:  Marcus Franz; Bernhard R Brehm; Petra Richter; Katja Gruen; Dario Neri; Hartwig Kosmehl; Khosro Hekmat; Andre Renner; Jan Gummert; Hans R Figulla; Alexander Berndt
Journal:  J Mol Histol       Date:  2010-03-16       Impact factor: 2.611

5.  In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics.

Authors:  Ying Ann Chiao; Rogelio Zamilpa; Elizabeth F Lopez; Qiuxia Dai; Gladys P Escobar; Kevin Hakala; Susan T Weintraub; Merry L Lindsey
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

6.  Tenascin-C in chronic sclerosing sialadenitis.

Authors:  Apostolos Epivatianos; Fotis Iordanidis; Dimitrios Andreadis; Savas Iordanidis; Athanasios Poulopoulos; Anastasios Markopoulos
Journal:  Head Neck Pathol       Date:  2011-05-11

7.  Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation.

Authors:  Lei Song; Lai Wang; Fuqiang Li; Ada Yukht; Minghui Qin; Haley Ruther; Mingjie Yang; Aurelio Chaux; Prediman K Shah; Behrooz G Sharifi
Journal:  J Am Coll Cardiol       Date:  2017-09-26       Impact factor: 24.094

8.  Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury.

Authors:  Masashi Tamaoki; Kyoko Imanaka-Yoshida; Kazuto Yokoyama; Tomohiro Nishioka; Hiroyasu Inada; Michiaki Hiroe; Teruyo Sakakura; Toshimichi Yoshida
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

9.  Epicardium-derived progenitor cells require beta-catenin for coronary artery formation.

Authors:  Mónica Zamora; Jörg Männer; Pilar Ruiz-Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-07       Impact factor: 11.205

10.  Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C.

Authors:  Sai-ichi Tanaka; Takayoshi Sumioka; Norihito Fujita; Ai Kitano; Yuka Okada; Osamu Yamanaka; Kathleen C Flanders; Masayasu Miyajima; Shizuya Saika
Journal:  Mol Vis       Date:  2010-07-01       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.